RadioMedix, Inc.

09/12/2024

We are thrilled to announce a groundbreaking licensing agreement with Sanofi and Orano Med to advance next generation radioligand medicine for rare cancers. This collaboration marks a significant step forward in our mission to develop innovative treatments for patients in need. 🎆🎊🎉
https://www.globenewswire.com/news-release/2024/09/12/2944919/0/en/Press-Release-Sanofi-RadioMedix-and-Orano-Med-announce-licensing-agreement-on-next-generation-radioligand-medicine-for-rare-cancers.html

07/24/2024

RadioMedix, Inc. is a clinical-stage biotechnology company, based in Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. We commercialize radiopharmaceuticals for PET imaging and targeted alpha and beta-emitter therapy.

07/04/2024

🎇Happy Fourth of July! our office will be closed on July 4th as we celebrate the 4th of July, we honor the birth of the United States of America—the day when the Declaration of Independence was adopted in 1776

Let us remember the sacrifices of those who fought for our liberty and reflect on the principles that unite us. Our offices will be closed today, but we’ll be back to serve you tomorrow, July 5th.

Enjoy the fireworks, spend time with loved ones, and embrace the spirit of unity that defines our nation.
🧪

09/08/2020

Houston, TX and St. Louis, MO, Sept. 07, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that DetectnetTM (copper Cu 64 dotatate injection) was approved by the U.S. Food and Drug Administration (FDA). Detectnet is a positron emission tomography (PET) agent indicated for the localization of somatostatin receptor-positive neuroendocrine tumors (NETs) in adult patients. Curium expects to launch Detectnet immediately with doses available through various nuclear pharmacies or directly from Curium.

Houston, TX and St. Louis, MO, Sept. 07, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. and its commercial partner Curium announced today that DetectnetTM...

07/11/2020

ITM and RadioMedix announce Drug Master File Submission for ITM’s 68Ge/68Ga Generator GeGant® for the U.S. MarketI

ITM Isotopen Technologien München AG (ITM), a biotechnology and radiopharmaceutical group of companies, and RadioMedix Inc., a clinical stage biotechn

02/10/2020

Houston, TX, USA, and Garching, Germany, Feb. 10, 2020 (GLOBE NEWSWIRE) -- RadioMedix, and OncoBeta today announced the ex*****on of an exclusive distribution agreement for the next generation of W/Re-188 generators in the U.S. and Canada.

The OncoBeta® Tungsten (Wolfram)-188/Rhenium-188 (W/Re-188) Generators can be used for radiolabeling reactions or directly as a high dose liquid radioactive source. Rhenium-188 (Re-188) is a high energy-emitting radioisotope obtained from the W/Re-188 Generator. Re-188 has shown high efficiency and value for a variety of therapeutic applications in nuclear medicine, oncology, and interventional radiology/cardiology areas. Its advantageous physical properties, its potential low cost, and with a long-lived parent, make this generator an attractive option for clinical use. The high energy of the emission of Re-188 is particularly well suited for the effective pe*******on in solid tumors as well as skin cancers. Its total radiation dose delivered to tissues is comparable to other radionuclides used in therapy today.

Houston, TX, USA, and Garching, Germany, Feb. 10, 2020 (GLOBE NEWSWIRE) -- RadioMedix, and OncoBeta today announced the ex*****on of an exclusive...

01/04/2020

Houston, Jan. 03, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been selected for the 2019-2020 Commercialization Accelerator Program (CAP) by the National Institute of Health (NIH) SBIR/STTR (Small Business Innovation Research/Small Business Technology Transfer) program office. This award is following our two-years, $2.0 M Phase II SBIR funded in part with Federal funds from the National Cancer Institute, National Institutes of Health and Human Services, under Contract No HHSN261201800048C. The Contract focuses on the clinical development of 212Pb-AlphaMedix™ for the targeted alpha-emitter therapy (TAT) of neuroendocrine tumors.

Houston, Jan. 03, 2020 (GLOBE NEWSWIRE) -- RadioMedix Inc. is pleased to announce that the company has been selected for the 2019-2020 Commercialization...

08/28/2018

St. Louis and Houston, Aug. 26, 2018 (GLOBE NEWSWIRE) -- Curium and RadioMedix Inc. announce an exclusive agreement to develop and commercialize 64Cu-Dotatate, an investigational positron emission tomography (PET) diagnostic agent for patients with suspected Neuroendocrine Tumors (NETs). RadioMedix is currently engaged in Phase III clinical trials of the agent and expects to file a New Drug Application with the Food and Drug Administration in 2019. This partnership builds on the initial development work conducted by RadioMedix and will benefit from Curium’s regulatory, manufacturing, distribution, and commercial expertise.

St. Louis and Houston, Aug. 26, 2018 (GLOBE NEWSWIRE) -- Curium and RadioMedix Inc. announce an exclusive agreement to develop and commercialize 64Cu-Dotatate, an investigational positron emission tomography (PET) diagnostic agent for patients with suspected Neuroendocrine Tumors (NETs). RadioMedix....

01/10/2018

Houston, TX (USA) and Courbevoie (France), Jan. 10, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. and AREVA Med today announced the initiation in the United States of Phase 1 trial for AlphaMedixTM in patients with somatostatin receptor positive neuroendocrine tumors. AlphaMedixTM is composed of a somatostatin (SST) analogue radiolabeled with 212Pb, an isotope used for Targeted Alpha-emitter Therapy (TAT).

Houston, TX (USA) and Courbevoie (France), Jan. 10, 2018 (GLOBE NEWSWIRE) -- RadioMedix Inc. and AREVA Med today announced the initiation in the United States of Phase 1 trial for AlphaMedixTM in patients with somatostatin receptor positive neuroendocrine tumors. AlphaMedixTM is composed of a som...